Efficacy of aprepitant on postoperative nausea and vomiting: Assesement with patient-controlled prevention of nause and vomiting (PCPNV).

Efficacy of aprepitant on postoperative nausea and vomiting: Assesement with patient-controlled prevention of nause and vomiting (PCPNV). - Aprepitant inhibits PONV

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004167

Enrollment

Registered

2010-09-07

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing dento-oral surgery

Interventions

Aprepitant 125 mg was preoperatively administered in 20 patients undergoing oro-dental-surgeries and postoperative neusea and vomiting is evaluated. Metoclopramide 10 mg was administered just before

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients for surgical correction of bite

Exclusion criteria

Exclusion criteria: Patients with pregnancy, having vomiting with 24 h before surgery in any etiology, allergy to any medications to be used prtioperatively, hepatic and renal disfunction. Patients taking medications known to induce or inhibit cytochrome P-450 3A4.

Design outcomes

Primary

Measure	Time frame
Consumption of postoperative anti-emetic agent	—

Countries

Japan

Contacts

Public ContactSyomu

Tohoku University Graduate School of Dentistry Syomu

den-syomu@bereau.tohoku.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026